Progress your preclinical
drug development
with speed and certainty

Obesity

We have more than 15 years experience within preclinical obesity studies to help progress your drug candidate. We provide off-the-shelf diet-induced obese (DIO) rodent models for profiling the efficacy and mode of action of your compound on endpoints ranging from food intake over energy expenditure to whole-brain activation signatures.

Kidney (CKD/DKD)

Progress your drug discovery with Gubra’s broad portfolio of mouse models recapitulating acute and chronic kidney diseases. Our ReninAAV hypertension-accelerated diabetic kidney disease (DKD) mouse is one of the most advanced models available for profiling drug candidates with therapeutic potential in DKD.

CNS

Gubra’s unique 3D light sheet imaging platform can visualize drug distribution, map drug targets and quantify therapeutic responses in the intact brain at single cell resolution. Our fully automated light sheet imaging pipeline accommodates up to 100 brains per study with a fast turn-around time of 2.5 months. Get instant access to your imaging data in our interactive atlas-guided 3D brain-viewer.

Lung (IPF)

We provide end-to-end customized studies in our spirometry-confirmed and bleomycin-induced mouse models of idiopathic pulmonary fibrosis (IPF). Accelerate your drug candidate by exploring pivotal lung functional endpoints in combination with AI-assisted histopathological scoring and quantitative histology.

Heart (CVD)

Gubra offers hypertension-induced heart failure models as well as industry-standard models for atherosclerosis. State-of-the-art echocardiography as well as quantitative whole-heart 3D histology are standard analyses in our mouse models of cardiovascular diseases.

Intestine (IBD)

Our chronic DSS-IBD mouse is a state-of-the-art model of colitis with histopathological hallmarks of progressive fibrosis. We provide customized study designs to probe drug candidates for prophylactic and therapeutic effects on immune and fibrosis histological endpoints.

Diabetes

We are experts in preclinical diabetes research, and offer customized studies in canonical rodent models of type 2 and type 1 diabetes to guide development of your anti-diabetic compound. Study data provided by our multidisciplinary teams can inform about efficacy on metabolic and glycemic endpoints as well as whole-pancreas islet and β-cell numbers for interpreting mode of action.

3D imaging

Gubra’s light-sheet microscopy platform allows for 3D imaging of all organs in the mouse and rat. Our fully automated imaging pipeline works seamlessly in combination with our in vivo models and in-house developed AI-driven image analysis to ensure precision-mapping of drug distribution and quantification of histological endpoints.

Histology

RNAseq

We offer a full palette of advanced sequencing technologies, including bulk RNAseq, single-nucleus RNAseq, spatial transcriptomics and ATACseq. We accept most types of tissues, including fresh frozen or archival samples (FFPE). Trust Gubra for fast turnaround and expert bioinformatics. Get instant access to your data in GubraView, our interactive data viewer.

Non-rodent studies

Advance your preclinical drug candidate by performing PK and gut microbiome studies in minipigs, a non-rodent model of choice in late-stage preclinical drug development programs.